Field evaluation of dried blood spots for HIV-1 viral load monitoring in adults and children receiving antiretroviral treatment in Kenya: Implications for scale-up in resource-limited settings

Journal of Acquired Immune Deficiency Syndromes

Volumn 74, Issue 4, 2017, Pages 399-406

  Schmitz, Mary E ^a   Agolory, Simon ^a   Junghae, Muthoni ^a   Broyles, Laura N ^a   Kimeu, Muthusi ^b   Ombayo, Joseph ^c   Umuro, Mamo ^c   Mukui, Irene ^c   Alwenya, Kennedy ^b   Baraza, Moses ^b   Ndiege, Kenneth ^b   Mwalili, Samuel ^a   Rivadeneira, Emilia ^a   Ng'Ang'A, Lucy ^a   Yang, Chunfu ^a   Zeh, Clement ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c MINISTRY OF HEALTH   (Kenya)

Author keywords

dried blood spots; HIV; HIV RNA; Kenya; resource limited settings; viral load

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; VIRUS RNA;

ADULT; ANTIRETROVIRAL THERAPY; ARTICLE; CAPILLARY BLOOD; DRIED BLOOD SPOT TESTING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KENYA; MAJOR CLINICAL STUDY; MALE; MICROCIRCULATION; PATIENT MONITORING; PRIORITY JOURNAL; SCALE UP; VENOUS BLOOD; VIRUS LOAD; BLOOD; CHILD; DRUG EFFECTS; GENETICS; HEALTH CARE PLANNING; HIV INFECTIONS; ISOLATION AND PURIFICATION; MASS SCREENING; PROCEDURES; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; TREATMENT FAILURE; VIROLOGY;

ADULT; CHILD; DRIED BLOOD SPOT TESTING; HEALTH RESOURCES; HIV INFECTIONS; HIV-1; HUMANS; KENYA; MASS SCREENING; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; TREATMENT FAILURE; VIRAL LOAD;

EID: 85007164520     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000001275     Document Type: Article

References (30)

1. UNAIDS. Global AIDS Update: UNAIDS Report. Geneva, Switzerland: UNAIDS; 2016.
2. Fiscus SA, Cheng B, Crowe SM, et al. HIV-1 viral load assays for resource-limited settings. PLoS Med. 2006;3:e417.
3. Roberts T, Bygrave H, Fajardo E, et al. Challenges and opportunities for the implementation of virological testing in resource-limited settings. J Int AIDS Soc. 2012;15:17324.
4. Stevens WS, Marshall TM. Challenges in implementing HIV load testing in South Africa. J Infect Dis. 2010;201(suppl 1):S78-S84.
5. Elbeik T, Chen YM, Soutchkov SV, et al. Global cost modeling analysis of HIV-1 and HCV viral load assays. Expert Rev Pharmacoecon Outcomes Res. 2003;3:383-407.
6. Elbeik T, Dalessandro R, Loftus RA, et al. HIV-1 and HCV viral load cost models for bDNA: 440 Molecular System versus real-time PCR AmpliPrep/TaqMan test. Expert Rev Mol Diagn. 2007;7:723-753.
7. Sawe FK, McIntyre JA. Monitoring HIV antiretroviral therapy in resource-limited settings: Time to avoid costly outcomes. Clin Infect Dis. 2009;49:463-465.
8. Schneider K, Puthanakit T, Kerr S, et al. Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in resource-limited settings. AIDS. 2011;25:1143-1151.
9. Havlir DV, Marschner IC, Hirsch MS, et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med. 1998;339:1261-1268.
10. Keiser O, Tweya H, Boulle A, et al. Switching to second-line antiretroviral therapy in resource-limited settings: Comparison of programmes with and without viral load monitoring. AIDS. 2009;23: 1867-1874.
11. Sigaloff KC, Hamers RL, Wallis CL, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr. 2011;58:23-31.
12. Smith DM, Schooley RT. Running with scissors: Using antiretroviral therapy without monitoring viral load. Clin Infect Dis. 2008;46: 1598-1600.
13. Tucker JD, Bien CH, Easterbrook PJ, et al. Optimal strategies for monitoring response to antiretroviral therapy in HIV-infected adults, adolescents, children and pregnant women: A systematic review. AIDS. 2014;28(suppl 2):S151-S160.
14. Kantor R, Shafer RW, Follansbee S, et al. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS. 2004;18:1503-1511.
15. Goetz MB, Holodniy M, Poulton JS, et al. Utilization and access to antiretroviral genotypic resistance testing and results within the US Department of Veterans Affairs. J Acquir Immune Defic Syndr. 2006;41: 59-62.
16. Cozzi-Lepri A, Phillips AN, Ruiz L, et al. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS. 2007;21:721-732.
17. WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendations for a Public Health Approach. 2nd ed. Geneva, Switzerland: World Health Organization; 2016.
18. UNAIDS90-90-90 an Ambitious Treatment Target to Help End the AIDS Epidemic. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2014.
19. Roche-Molecular-Diagnostics. Global Access Program FAQ Document. Pleasanton, CA: Roche Molecular Systems; 2015.
20. Fajardo E, Metcalf CA, Chaillet P, et al. Prospective evaluation of diagnostic accuracy of dried blood spots from finger prick samples for determination of HIV-1 load with the NucliSENS Easy-Q HIV-1 version 2.0 assay in Malawi. J Clin Microbiol. 2014;52:1343-1351.
21. Napierala Mavedzenge S, Davey C, Chirenje T, et al. Finger prick dried blood spots for HIV viral load measurement in field conditions in Zimbabwe. PLoS One. 2015;10:e0126878.
22. Rutstein SE, Kamwendo D, Lugali L, et al. Measures of viral load using Abbott RealTime HIV-1 Assay on venous and fingerstick dried blood spots from provider-collected specimens in Malawian District Hospitals. J Clin Virol. 2014;60:392-398.
23. Jennings CH, Granger B, Wager S, et al. Cross-platform analysis of HIV-1 RNA data generated by multicenter assay validation study with wide geographic representation. J Clin Microbiol. 2012;50:2737-2747.
24. Andreotti M, Pirillo M, Guidotti G, et al. Correlation between HIV-1 viral load quantification in plasma, dried blood spots, and dried plasma spots using the Roche COBAS Taqman assay. J Clin Virol. 2010;47:4-7.
25. Sawadogo S, Shiningavamwe A, Chang J, et al. Limited utility of dried blood and plasma spot based screening for antiretroviral treatment failure with COBAS Ampliprep/TaqMan HIV-1 v2.0. J Clin Microbiol. 2014; 52:3878-3883.
26. Arredondo M, Garrido C, Parkin N, et al. Comparison of HIV-1 RNA measurements obtained by using plasma and dried blood spots in the automated abbott real-time viral load assay. J Clin Microbiol. 2012;50: 569-572.
27. NASCOP. Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: A Rapid Advice, 2014. Nairobi, Kenya: Ministry of Health, Government of Kenya; 2014.
28. Boillot F, Serrano L, Muwonga J, et al. Implementation and operational research: Programmatic feasibility of dried blood spots for the virological follow-up of patients on antiretroviral treatment in Nord Kivu, Democratic republic of the Congo. J Acquir Immune Defic Syndr. 2016;71:e9-e15.
29. Rutstein SE, Hosseinipour MC, Kamwendo D, et al. Dried blood spots for viral load monitoring in Malawi: Feasible and effective. PLoS One. 2015;10:e0124748.
30. Wu X, Crask M, Ramirez H, et al. A simple method to elute cell-free HIV from dried blood spots improves their usefulness for monitoring therapy. J Clin Virol. 2015;65:38-40.